| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Timothy J Wilt | Q107974776 |
| P2093 | author name string | Roderick MacDonald | |
| James Tacklind | |||
| Indy Rutks | |||
| P2860 | cites work | Associating Serenoa Repens, Urtica Dioica and Pinus Pinaster. Safety and Efficacy in the Treatment of Lower Urinary Tract Symptoms. Prospective Study on 320 Patients | Q85125460 |
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Serenoa repens for benign prostatic hyperplasia | Q28215754 | ||
| Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia | Q28277055 | ||
| Saw palmetto for benign prostatic hyperplasia | Q28296308 | ||
| Complementary and alternative medicine use among adults: United States, 2002 | Q29615129 | ||
| Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial | Q30424857 | ||
| Clinical trials in psychiatry: should protocol deviation censor patient data? | Q30982746 | ||
| Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review | Q31973506 | ||
| Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia | Q34309375 | ||
| Treatment of benign prostatic hyperplasia with phytosterols | Q34571798 | ||
| Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract | Q35854081 | ||
| Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action | Q35947120 | ||
| Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention | Q36587597 | ||
| Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union | Q37389084 | ||
| Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients | Q39461920 | ||
| Plant extracts in BPH. | Q40390459 | ||
| Phytotherapy in treatment of benign prostatic hyperplasia: a critical review | Q41023513 | ||
| Phytotherapy for the prostate | Q41177287 | ||
| The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine | Q41727393 | ||
| Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia | Q41728697 | ||
| A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia | Q42531516 | ||
| Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers | Q42687230 | ||
| Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. | Q43718452 | ||
| Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens | Q43975694 | ||
| Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). | Q44046663 | ||
| Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study | Q44110392 | ||
| Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial | Q44110394 | ||
| Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism | Q44183932 | ||
| The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia | Q44697461 | ||
| Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis | Q44900802 | ||
| Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia | Q45219179 | ||
| The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group | Q45335490 | ||
| Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago | Q46558363 | ||
| [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]. | Q50794535 | ||
| Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. | Q52057618 | ||
| Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. | Q53051177 | ||
| A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. | Q53243983 | ||
| Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. | Q53257066 | ||
| Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial. | Q53272579 | ||
| Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. | Q53333416 | ||
| BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. | Q53853603 | ||
| Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract ofSerenoa repens (LSESr, Permixon�) in benign prostatic hyperplasia | Q63966511 | ||
| The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. | Q64943372 | ||
| Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients | Q67465301 | ||
| Conservative, non-hormonal treatment of benign prostatic hyperplasia | Q67655658 | ||
| Variance imputation for overviews of clinical trials with continuous response | Q68186031 | ||
| [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo] | Q68943952 | ||
| The value of permixon in benign prostatic hypertrophy | Q68954491 | ||
| Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia | Q71022039 | ||
| Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research | Q71607388 | ||
| Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia | Q71690849 | ||
| Growing use of medicinal botanicals forces assessment by drug regulators | Q72518273 | ||
| The development of human benign prostatic hyperplasia with age | Q72743475 | ||
| Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo | Q73071794 | ||
| Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial | Q73725383 | ||
| [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study] | Q73813066 | ||
| [Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study] | Q74011397 | ||
| Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men | Q74179430 | ||
| Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms | Q74605848 | ||
| Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms | Q77355302 | ||
| Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia | Q78704454 | ||
| Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China | Q80204623 | ||
| [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study] | Q81426137 | ||
| [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial] | Q83365984 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostatic hypertrophy | Q506659 |
| Serenoa repens | Q927607 | ||
| P304 | page(s) | CD001423 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Serenoa repens for benign prostatic hyperplasia |
| Q37730835 | A green and black tea extract benefits urological health in men with lower urinary tract symptoms |
| Q33795105 | Acute liver damage due to Serenoa repens: a case report |
| Q38541942 | Acute pancreatitis with saw palmetto use: a case report |
| Q24608047 | An update on plant derived anti-androgens |
| Q35231660 | Androgens and estrogens in benign prostatic hyperplasia: past, present and future |
| Q37994725 | Combination pharmacological therapies for the management of benign prostatic hyperplasia |
| Q37801275 | Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. |
| Q49040330 | Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study |
| Q41986288 | Diagnosis and management of benign prostatic hyperplasia in primary care. |
| Q30424857 | Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial |
| Q41111726 | Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study |
| Q38901253 | Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene |
| Q30427093 | Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia |
| Q30432603 | Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia |
| Q37026868 | Safety and toxicity of saw palmetto in the CAMUS trial |
| Q37942163 | Serenoa repens extract in the treatment of benign prostatic hyperplasia |
| Q24202555 | Serenoa repens for benign prostatic hyperplasia |
| Q27015007 | Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review |
| Q30413910 | The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial |
| Q34789608 | The shrinking case for saw palmetto |
| Q35550448 | Towards the prevention and management of prostatic diseases in Nigeria: a framework. |
Search more.